Drugs / TQB3473
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04412577 | Oct 2020 → Dec 2021 | hematopoietic and lymphoid system neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07083739 | Aug 2025 → Sep 2027 expected | primary thrombocytopenia | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06900920 Comparator | Apr 2025 → Mar 2027 expected | primary thrombocytopenia | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3473 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07083739 ↗ |
| Action | Inhibit | “TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.” NCT06900920 ↗ |
| Route | Oral | “TQB3473 tablets administered orally once.” NCT04412577 ↗ |
| Target | SYK | “TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.” NCT06900920 ↗ |